CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 1, 2005, Pages 180-190

  Galetin, Aleksandra ^a   Ito, Kiyomi ^b   Hallifax, David ^a   Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; NIFEDIPINE; QUINIDINE; TESTOSTERONE;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; DRUG INHIBITION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME SPECIFICITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; KINETICS; LIVER MICROSOME; PREDICTION; PRIORITY JOURNAL; URINARY EXCRETION;

ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; AREA UNDER CURVE; AZOLES; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FORECASTING; HUMANS; HYPNOTICS AND SEDATIVES; KINETICS; MICROSOMES; MIDAZOLAM; NIFEDIPINE; QUINIDINE; SUBSTRATE SPECIFICITY; TESTOSTERONE;

EID: 23044500208     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.082826     Document Type: Article

References (61)

1. Ahonen J, Olkkola KT, and Neuvonen PJ (1995) Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 40:270-272.
2. Armitage P, Berry G, and Matthews JNS (2002) Analysing non-normal data, in Statistical Methods in Medical Research, pp 272-311, Blackwell Science, Oxford.
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
4. Backman JT, Kivisto KT, Olkkola KT, and Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53-58.
5. Benet LZ, Cummins CL, and Wu CY (2004) Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharmaceut 277:3-9.
6. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, and Matas AJ (1991) Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 51:1014-1018.
7. Egnell A-C, Eriksson C, Albertson N, Houston JB, and Boyer S (2003) Generation and evaluation of CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther 307:878-887.
8. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
9. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, and Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606.
10. Foradori A, Mezzano S, Videla C, Pefaur J, and Elberg A (1998) Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. Transplant Proc 30:1685-1687.
11. Galetin A, Brown C, Hallifax D, Ito K, and Houston JB (2004) Utility of recombinant enzyme kinetics in prediction of human clearance -impact of variability, CYP3A5 and CYP2C19 on CYP3A4 substrates. Drug Metab Dispos 32 1411-1420.
12. Galetin A, Clarke SE, and Houston JB (2002) Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 30:1512-1522.
13. Galetin A, Clarke SE, and Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone and nifedipine. Drug Metab Dispos 31:1108-1116.
14. i values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
15. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, and Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
16. Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, and Shader RI (1998) Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 64:237-247.
17. Haufroid V, Mourad M, van Kerckhove V, Wawrzyniak J, de Meyer M, Eddour DC, Malaise J, Lison D, Squifflet J-P, and Wallemacq P (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147-154.
18. Heinig R, Adelmann HG, and Ahr G (1999) The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine. Eur J Clin Pharmacol 55:57-60.
19. Houston JB and Galetin A (2003) Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab Rev 35:393-415.
20. Houston JB and Galetin A (2005) Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 433:351-360.
21. Houston JB, Kenworthy KE, and Galetin A (2003) Typical and atypical enzyme kinetics, in Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development (Fisher M, Lee J, and Obach S eds) pp 211-254, FontisMedia, Lausanne, Switzerland.
22. Huang W, Lin YS, McConn IIDJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
23. Hutzler JM, Wienkers LC, Wahlstrom JL, Carlson TJ, and Tracy TS (2003) Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys 410:16-24.
24. Isoherranen N, Kunze KL, Allen KE, Nelson WL, and Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121-1131.
25. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data [published erratum appears in Br J Clin Pharmacol (2004) 58:565-568]. Br J Clin Pharmacol 57:473-486.
26. Jalava KM, Olkkola KT, and Neuvonen PJ (1997) Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 61:410-415.
27. Kantola T, Kivisto KT, and Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65.
28. Kantola T, Kivisto KT, and Neuvonen PJ (1999) Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol 54:851-855.
29. Karyekar CS, Eddington ND, Briglia A, Gubbins PO, and Dowling TC (2004) Renal interaction between itraconazole and cimetidine. J Clin Pharmacol 44:919-927.
30. Kaukonen K-M, Olkkola KT, and Neuvonen PJ (1997) Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 62:510-517.
31. Kenworthy K, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of ten in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
32. Kivisto KT, Kantola T, and Neuvonen PJ (1998) Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 46:49-53.
33. Korzekwa K (2002) In vitro enzyme kinetics applied to drug-metabolizing enzymes, in Drug-Drug Interactions (Rodrigues AD ed) pp 33-54, Marcel Dekker, New York.
34. Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal metabolism of midazolam. Mol Pharmacol 62:162-172.
35. Nestorov I, Gueorguieva I, Jones H, Houston JB, and Rowland M (2002) Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data. Drug Metab Dispos 30:276-282.
36. Neuvonen PJ and Jalava KM (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60:54-61.
37. Neuvonen PJ, Kantola T, and Kivisto KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332-341.
38. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
39. Olkkola KT, Ahonen J, and Neuvonen PJ (1996) The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82:511-516.
40. Olkkola KT, Backman JT, and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
41. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
42. Rostami-Hodjegan A and Tucker GT (2004) 'In silico ' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today 1:441-448.
43. Rowland M and Matin SB (1973) Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1:553-567.
44. Segel IH (1975) Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady State enzyme Systems, Wiley & Sons, Inc., New York.
45. Sheiner LB and Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512.
46. Stresser DM, Blanchard AP, Turner SD, Erve JCL, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
47. Tang W and Stearns RA (2001) Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2:185-198.
48. Tolle-Sander S, Rautio J, Wring S, Polli JW, and Polli JE (2003) Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 20:757-764.
49. Trapnell CB, Narang PK, Li R, and Lavelle JP (1996) Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 124:573-576..
50. Tucker GT, Houston JB, and Huang S-M (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Clin Pharmacol Ther 70:103-114.
51. Uchaipichat V, Mackenzie PI, Guo X-H, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
52. Varhe A, Olkkola KT, and Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther 56:601-607.
53. Varhe A, Olkkola KT, and Neuvonen PJ (1996a) Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 42:465-470.
54. Varhe A, Olkkola KT, and Neuvonen PJ (1996b) Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 41:319-323.
55. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
56. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5 and CYP3A7. Drug Metab Dispos 30:883-891.
57. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, and Gurney H (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 14:471-478.
58. Xie H-G, Wood AJJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.
59. Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, and Sugawara K (1998) Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 139:269-273.
60. Yuan R, Madani S, Wei X-X, Reynolds K, and Huang S-M (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319.
61. Zhang Y and Benet LZ (2001) The gut as a barrier to drug absorption. Clin Pharmacokinet 40:159-168.